Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy

NCT04099641 is registered in ClinicalTrials.gov with OncXerna Theraputics, Inc. as lead sponsor.

NCT NCT04099641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04099641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy
Lead sponsor
OncXerna Theraputics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 11, 2019
Completion date
October 26, 2022
Enrollment
80 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal cancer